Therapeutic development paths for cognitive impairment in Parkinson's disease: Report of a regulatory roundtable

摘要: Cognitive impairment is a common occurrence in Parkinson's disease (PD), although the severity and specific presentation varies across patients. Initial deficits, including mild cognitive (PD-MCI), may remain stable or many cases, progress over variable lengths of time to dementia (PDD). As there are currently no marketed treatments for milder forms impairment, an opportunity exists define path therapeutic development this area. In absence well-defined approval therapies that target PD-MCI, pharmaceutical companies unlikely pursue indication. order move forward improve quality life PD patients, it imperative field have consensus on definition best instruments measure decline, strategy future clinical trials.